Search details
1.
Oncostatin M and Nivolumab Affect the Cytotoxic T-Cell Proportions and the Susceptibility to TRAIL-Induced Death in Non-Leukocyte Cell Subpopulations in Soft Tissue Sarcomas.
Pharmacology
; 108(3): 274-285, 2023.
Article
in English
| MEDLINE | ID: mdl-36996792
2.
Accelerated Maturation, Exhaustion, and Senescence of T cells in 22q11.2 Deletion Syndrome.
J Clin Immunol
; 42(2): 274-285, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34716533
3.
The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
BMC Cancer
; 22(1): 1021, 2022 Sep 28.
Article
in English
| MEDLINE | ID: mdl-36171566
4.
Principles and Challenges in anti-COVID-19 Vaccine Development.
Int Arch Allergy Immunol
; 182(4): 339-349, 2021.
Article
in English
| MEDLINE | ID: mdl-33524979
5.
Principles and new perspectives in the vaccination against SARS-CoV-2 virus.
Cas Lek Cesk
; 159(7-8): 298-302, 2020.
Article
in English
| MEDLINE | ID: mdl-33445936
6.
Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies.
Pathogens
; 12(1)2023 Jan 09.
Article
in English
| MEDLINE | ID: mdl-36678457
7.
Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?
Pharmaceuticals (Basel)
; 16(3)2023 Feb 27.
Article
in English
| MEDLINE | ID: mdl-36986462
8.
Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy.
Int Immunopharmacol
; 125(Pt B): 111159, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37956487
9.
A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade.
J Cancer Res Clin Oncol
; 149(7): 3789-3801, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-35986756
10.
Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.
J Allergy Clin Immunol Pract
; 11(1): 306-314.e2, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36379409
11.
Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs.
Front Immunol
; 13: 1010808, 2022.
Article
in English
| MEDLINE | ID: mdl-36211417
12.
SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients.
Front Immunol
; 13: 1017232, 2022.
Article
in English
| MEDLINE | ID: mdl-36439163
13.
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study.
Front Immunol
; 13: 835770, 2022.
Article
in English
| MEDLINE | ID: mdl-35296097
14.
An immunologist's perspective on anti-COVID-19 vaccines.
Curr Opin Allergy Clin Immunol
; 21(6): 545-552, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-34545040
15.
Novel XIAP mutation causing enhanced spontaneous apoptosis and disturbed NOD2 signalling in a patient with atypical adult-onset Crohn's disease.
Cell Death Dis
; 11(6): 430, 2020 06 08.
Article
in English
| MEDLINE | ID: mdl-32514016
16.
Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils' but Impaired Monocytes' and Dendritic Cells' Responsiveness.
Cells
; 9(10)2020 09 29.
Article
in English
| MEDLINE | ID: mdl-33003471
17.
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab.
Lancet Rheumatol
; 4(3): e163-e166, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34957418
Results
1 -
17
de 17
1
Next >
>>